Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Former CDER Chief Galson Moving To Amgen

This article was originally published in The Pink Sheet Daily

Executive Summary

Galson, who went to FDA in 2001 to deal with post-marketing surveillance issues, will arrive in time for Aranesp advisory committee meeting.

You may also be interested in...



Amgen Shortens Epogen, Procrit Shelf-lives Following Recall

Firm is working with vial manufacturers to determine the cause of the delamination.

Amgen Shortens Epogen, Procrit Shelf-lives Following Recall

Firm is working with vial manufacturers to determine the cause of the delamination.

PDUFA’s Fairy Godmother: Woodcock Steps Into Breach As Acting CDER Chief

Faced with the departure of Steven Galson as CDER director just as major new drug safety authorities have been bestowed upon FDA, Commissioner Andrew von Eschenbach has turned to former CDER director Janet Woodcock to provide a practiced hand on the wheel of change until a permanent replacement can be found

Topics

UsernamePublicRestriction

Register

PS071213

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel